Other languages Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
6.16 ^USD	+2.67%		+14.29%	-31.48%

24/04	EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	MT
24/04	Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	24/04
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	04/04
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy	11/03
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy	11/03
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease	23/02
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy	23/02
Travere drug for rare kidney condition recommended for EU approval	23/02
Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	16/02
Sector Update: Health Care Stocks Mixed Premarket Friday	26/01
Travere Therapeutics Signs Licensing Agreement With Renalys Pharma for Rare Kidney Disease Therapy	26/01
Travere Therapeutics, Inc. Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations	26/01
Travere Therapeutics Expects $40 Million in Q4 Net Product Sales	08/01
Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	08/01
Travere Therapeutics, Inc. Announces Program Updates and Anticipated 2024 Milestones	08/01
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria	14/12
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	05/12
Sector Update: Health Care	05/12
Travere Therapeutics Says Pre-NDA Meeting With FDA for IgA Nephropathy Drug 'Successful'; Plans 20% Job Cut; Shares Jump Pre-Bell	05/12
Travere Therapeutics, Inc. Completes Successful Pre-NDA Meeting for FILSPARI in IgAN	05/12
Travere Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Other languages

Filters